These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29975243)

  • 1. Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis.
    Hill LA; Delmonte RJ; Andrews B; Richards L; Soto R; Collier S; Kuo A; Cachay E
    Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1378-1383. PubMed ID: 29975243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.
    Maier MM; Zhou XH; Chapko M; Leipertz SL; Wang X; Beste LA
    Dig Dis Sci; 2018 Jun; 63(6):1454-1462. PubMed ID: 29453610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
    Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.
    Singer AW; Reddy KR; Telep LE; Osinusi AO; Brainard DM; Buti M; Chokkalingam AP
    Aliment Pharmacol Ther; 2018 May; 47(9):1278-1287. PubMed ID: 29516535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
    Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
    Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection.
    Weiler N; Zeuzem S; Welker MW
    World J Gastroenterol; 2016 Nov; 22(41):9044-9056. PubMed ID: 27895394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.
    Fernández Carrillo C; Lens S; Llop E; Pascasio JM; Crespo J; Arenas J; Fernández I; Baliellas C; Carrión JA; de la Mata M; Buti M; Castells L; Albillos A; Romero M; Turnes J; Pons C; Moreno-Planas JM; Moreno-Palomares JJ; Fernández-Rodriguez C; García-Samaniego J; Prieto M; Fernández Bermejo M; Salmerón J; Badia E; Salcedo M; Herrero JI; Granados R; Blé M; Mariño Z; Calleja JL
    Hepatology; 2017 Jun; 65(6):1810-1822. PubMed ID: 28170112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy.
    Vaziri A; Gimson A; Agarwal K; Aldersley M; Bathgate A; MacDonald D; McPherson S; Mutimer D; Gelson W
    J Viral Hepat; 2019 Feb; 26(2):231-235. PubMed ID: 30339294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.
    Park H; Wang W; Henry L; Nelson DR
    Hepatology; 2019 Mar; 69(3):1032-1045. PubMed ID: 30289989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
    Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
    World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.
    Jiang X; Vouri SM; Diaby V; Lo-Ciganic W; Parker R; Park H
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1388-1402. PubMed ID: 34595949
    [No Abstract]   [Full Text] [Related]  

  • 13. Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.
    Song AT; Sobesky R; Vinaixa C; Dumortier J; Radenne S; Durand F; Calmus Y; Rousseau G; Latournerie M; Feray C; Delvart V; Roche B; Haim-Boukobza S; Roque-Afonso AM; Castaing D; Abdala E; D'Albuquerque LA; Duclos-Vallée JC; Berenguer M; Samuel D
    World J Gastroenterol; 2016 May; 22(18):4547-58. PubMed ID: 27182164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
    Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era.
    Cacoub P; Vautier M; Desbois AC; Lafuma A; Saadoun D
    Liver Int; 2017 Dec; 37(12):1805-1813. PubMed ID: 28467688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained Virologic Response of Patients Hospitalized Compared With Those Not Hospitalized During Treatment for Hepatitis C Virus With Direct-Acting Antivirals.
    Gentene AJ; Bell AM; Pence A; Thomas K; Jakubecz C; Stacy E; Woolf B; Guido MR; Mueller EW; Sherman KE
    Ann Pharmacother; 2021 May; 55(5):565-574. PubMed ID: 33016095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study.
    Kieran JA; Norris S; O'Leary A; Walsh C; Merriman R; Houlihan D; McCormick PA; McKiernan S; Bergin C; Barry M
    BMC Infect Dis; 2015 Oct; 15():471. PubMed ID: 26503519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare Beneficiaries.
    Jung J; Feldman R; Kalidindi Y; Riley T
    JAMA Netw Open; 2020 Jun; 3(6):e208081. PubMed ID: 32602909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrosis Regression Explains Differences in Outcome in HIV-/HCV-Coinfected Patients with Cirrhosis After Sustained Virological Response.
    Casado JL; Esteban MA; Bañón S; Moreno A; Perez-Elías MJ; Mateos ML; Moreno S; Quereda C
    Dig Dis Sci; 2015 Nov; 60(11):3473-81. PubMed ID: 26112991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
    Grottenthaler JM; Werner CR; Steurer M; Spengler U; Berg T; Engelmann C; Wedemeyer H; von Hahn T; Stremmel W; Pathil A; Seybold U; Schott E; Blessin U; Sarrazin C; Welker MW; Harrer E; Scholten S; Hinterleitner C; Lauer UM; Malek NP; Berg CP
    PLoS One; 2018; 13(6):e0197544. PubMed ID: 29874250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.